Fisetin: The Senolytic Flavonoid You Should Know About

If you follow longevity medicine, you have probably seen fisetin mentioned alongside dasatinib and quercetin as a senolytic agent — a compound that selectively clears senescent cells. What makes fisetin interesting is that it is a naturally occurring flavonoid, it is available as a supplement, and the preclinical data is genuinely compelling. What makes it complicated is that the human data is still early, the bioavailability is problematic, and the gap between animal promise and clinical proof remains wide.

Here is what the research actually says, what we are seeing in practice, and how to think about fisetin if you are considering it.

At a Glance

Fisetin Senolytic Dosing: The Science Behind the Compound

What Are Senescent Cells?

I covered senolytic therapy in detail in a previous article, but the essential context: senescent cells are damaged cells that have stopped dividing but refuse to die. Instead, they persist in tissues and secrete a toxic cocktail of inflammatory cytokines, growth factors, and proteases called the senescence-associated secretory phenotype — SASP.

This secretory phenotype is not benign. It drives chronic inflammation, disrupts tissue homeostasis, promotes fibrosis, and accelerates the aging of surrounding healthy cells. Senescent cells accumulate with age, and their burden correlates with age-related diseases including cardiovascular disease, neurodegeneration, pulmonary fibrosis, and cancer.

The senolytic hypothesis is conceptually elegant: selectively kill these zombie cells, and you remove a major driver of aging and chronic disease. The animal evidence supporting this hypothesis is among the most striking in all of geroscience.

Why Fisetin?

In 2018, Yousefzadeh and colleagues at the Mayo Clinic published a landmark screen of 10 flavonoids for senolytic activity [1]. The methodology was straightforward: test each compound’s ability to selectively kill senescent human umbilical vein endothelial cells (HUVECs) while sparing non-senescent cells.

Fisetin emerged as the most potent senolytic in the screen — more potent than quercetin, luteolin, or curcumin. In mouse models, fisetin treatment:

• Reduced senescent cell markers in multiple tissues
• Decreased SASP factor expression
• Extended median and maximum lifespan in aged mice
• Improved tissue function in organs affected by senescent cell accumulation

This paper drove enormous interest in fisetin within the longevity community. A natural, purchasable compound with dramatic effects on aging in mice — the appeal was obvious.

But let me be clear about the evidence hierarchy. This is preclinical data. Mice are not humans. The history of medicine is littered with interventions that worked beautifully in animal models and failed in human trials. Fisetin’s preclinical promise is real and important, but it is not clinical proof.

The Mechanism: How Fisetin Kills Senescent Cells

Senescent cells resist apoptosis (programmed cell death) through upregulated survival pathways. They are not immortal — they are actively suppressing their own death. Fisetin targets several of these survival mechanisms:

PI3K/AKT pathway inhibition: Fisetin inhibits phosphoinositide 3-kinase signaling, which senescent cells use to maintain survival. This pathway is constitutively activated in many senescent cell types and represents a vulnerability that normal cells do not share to the same degree [2].

BCL-2 family modulation: The BCL-2 protein family includes both pro-survival (BCL-2, BCL-xL) and pro-apoptotic (BAX, BAK) members. Senescent cells upregulate pro-survival BCL-2 proteins to resist death. Fisetin shifts this balance toward apoptosis by reducing BCL-2 and BCL-xL expression [1].

HIF-1alpha suppression: Hypoxia-inducible factor 1-alpha is another survival factor that is elevated in senescent cells. Fisetin suppresses HIF-1alpha signaling, further weakening the senescent cell’s resistance to apoptosis [3].

NF-kB pathway modulation: Beyond direct senolytic effects, fisetin also suppresses NF-kB-mediated inflammatory signaling, which reduces the inflammatory burden of the SASP even before senescent cell clearance is complete.

The selectivity is the key insight. Normal, healthy cells are not dependent on these survival pathways to the same extent. At senolytic concentrations, fisetin preferentially tips senescent cells over the apoptotic threshold while leaving healthy cells relatively unaffected.

The Evidence: Animal, Human, and the Gap Between

Animal Data (Strong and Consistent)

The preclinical evidence for fisetin’s senolytic activity is robust:

Yousefzadeh et al. (2018): The seminal Mayo Clinic study. Fisetin treatment in aged mice (equivalent to ~75 human years) reduced senescent cell burden, decreased SASP markers, and extended median lifespan. Late-life intervention was effective — you did not have to start young [1].

Replicated findings: Subsequent studies confirmed fisetin’s senolytic activity in multiple tissue types and disease models, including osteoarthritis, kidney disease, and frailty models [4].

Combination effects: Fisetin has shown additive or synergistic effects when combined with other senolytic agents in preclinical models, suggesting potential for combination protocols.

Important caveats: Mouse senolytics research uses doses that, when scaled to humans by body surface area, suggest high doses are needed — and the bioavailability in mice may differ significantly from humans.

Human Data (Emerging and Mixed)

This is where the honest assessment becomes critical.

The AFFIRM-LITE Trial: The most important human study to date, conducted at the Mayo Clinic. This pilot trial evaluated fisetin (20 mg/kg/day for 2 consecutive days) in older adults. The results:

• Some reduction in circulating SASP biomarkers
• Trends toward improved physical function measures
• Good tolerability with no serious adverse events
• The magnitude of effect was modest — not the dramatic results the preclinical data had led some to expect [5]

The context: AFFIRM-LITE was a small, short-duration pilot study. It was designed to assess safety and preliminary efficacy signals, not to definitively prove senolytic efficacy. The fact that it showed some positive signals is encouraging. The fact that it did not show dramatic effects deserves honest acknowledgment.

Ongoing trials: Larger fisetin trials are underway for chronic kidney disease, osteoarthritis, and age-related frailty. These will provide more definitive data on clinical efficacy.

Bridging the Gap

In my assessment, fisetin sits in the “emerging evidence” category — stronger than speculative but not yet clinically validated. The preclinical rationale is solid. The preliminary human data is cautiously encouraging. The definitive human trials are in progress.

What I observe in practice: some patients who incorporate intermittent high-dose fisetin report subjective improvements in energy, inflammatory markers, and general wellbeing. These observations are not controlled, and I am careful to present them as clinical impressions rather than evidence. But when I combine these observations with the mechanistic data and preclinical results, I consider fisetin a reasonable component of a senolytic protocol — with transparent communication about evidence limitations.

Fisetin Dosing: The Protocol

Why Intermittent High-Dose, Not Daily Low-Dose

This is a critical point that many supplement users get wrong. Senolytic dosing is fundamentally different from standard supplementation.

The goal is not to maintain a constant low blood level of fisetin. The goal is to achieve a high enough concentration to trigger apoptosis in senescent cells during a brief treatment window. Senescent cells are cleared, healthy cells recover, and you wait for the next cycle.

Think of it like this: you are not watering a garden (steady, low-dose). You are weeding (intensive, periodic removal).

Why daily low-dose does not work as a senolytic:

• Standard supplement doses (100-500 mg/day) likely do not achieve senolytic concentrations in tissues
• At low doses, fisetin’s antioxidant and anti-inflammatory properties may actually protect senescent cells from apoptotic triggers rather than killing them
• The preclinical senolytic studies used intermittent high-dose protocols, not chronic low-dose administration

The Standard Protocol

Based on the Mayo Clinic research protocol and adapted for clinical use:

Practical dosing for an 80 kg (176 lb) individual:

• Day 1: 1,600 mg fisetin (e.g., 800 mg morning, 800 mg evening) with fatty meals
• Day 2: 1,600 mg fisetin (same schedule)
• Then stop until the next cycle

Bioavailability: The Elephant in the Room

Here is the problem that most fisetin discussions understate: standard fisetin has extremely poor oral bioavailability. Estimates range from 5-15%, depending on the formulation and individual variation [6].

This means that of 1,600 mg taken orally, only 80-240 mg may reach systemic circulation. Whether this achieves senolytic concentrations in target tissues is genuinely uncertain.

Strategies to improve bioavailability:

Take with fat: Fisetin is lipophilic. Fat-containing meals improve absorption — a principle that applies to most flavonoids.

Piperine (black pepper extract): May improve absorption by inhibiting glucuronidation in the gut and liver, similar to its effect on curcumin. Evidence is limited but the mechanism is sound.

Liposomal formulations: Liposomal encapsulation can dramatically improve flavonoid bioavailability. Some manufacturers now offer liposomal fisetin, though independent verification of liposome quality varies.

Galenic formulations: Novel delivery systems using cyclodextrins, nanoparticles, or self-emulsifying drug delivery systems are under development. These are not yet widely available as supplements.

In my clinical practice, I recommend liposomal fisetin when available, taken with a fat-containing meal, as the current best approach to the bioavailability problem. I am transparent with patients that even with these measures, we cannot be certain we are achieving senolytic tissue concentrations.

Fisetin Combined With Quercetin: Does It Make Sense?

The combination question comes up frequently, and the logic is reasonable:

Quercetin is the senolytic partner in the dasatinib + quercetin (D+Q) protocol — the most extensively studied senolytic combination. Quercetin inhibits PI3K, BCL-2, and serpine anti-apoptotic pathways.

Fisetin has overlapping but not identical targets. Both are flavonoids, but fisetin appears to have greater senolytic potency per the Mayo Clinic screen [1].

Combination rationale: Different flavonoids may target different senescent cell populations or different survival pathways within the same cells. Combining fisetin and quercetin could theoretically provide broader senolytic coverage.

The evidence for the combination: There are no published human trials specifically evaluating fisetin + quercetin together. The rationale is mechanistic, not clinical.

My approach: For patients pursuing senolytic protocols without dasatinib (which requires prescription), I consider a fisetin + quercetin combination during the 2-day intermittent protocol reasonable:

This is a clinical hypothesis, not a proven protocol. I want to be explicit about that distinction.

Food Sources: Can You Get Enough From Diet?

Fisetin is found naturally in several fruits and vegetables:

Let me do the math: to achieve a senolytic dose of 1,600 mg of fisetin from strawberries alone, you would need to eat approximately 10 kilograms — about 22 pounds — of strawberries in a single day. This is not practical.

Dietary fisetin intake from a fruit-rich diet is estimated at 0.2-1.0 mg/day [7]. This is 1,000-8,000 times lower than the senolytic dosing protocol.

The takeaway: dietary fisetin provides general antioxidant and anti-inflammatory benefits. It does not provide senolytic-level dosing. For senolytic purposes, supplementation at therapeutic doses is required.

Safety and Considerations

Fisetin has a favorable safety profile based on available data:

Published trial data: No serious adverse events in human trials at senolytic doses (20 mg/kg). Mild GI symptoms (nausea, loose stools) have been reported [5].

Natural history of dietary exposure: Humans have consumed fisetin-containing foods for millennia. The compound has well-characterized metabolism and no documented toxicity at food-level doses.

Drug interactions: Fisetin inhibits certain cytochrome P450 enzymes (CYP3A4, CYP2C9) at high concentrations [8]. During the 2-day high-dose protocol, patients on medications metabolized by these enzymes (statins, warfarin, some antidepressants) should discuss timing with their prescribing physician.

Anticoagulant effects: Fisetin has mild antiplatelet activity. Patients on blood thinners should exercise caution and inform their physician.

Immune function consideration: Senescent cells are not entirely harmful — cellular senescence plays important roles in wound healing, tissue repair, and tumor suppression. Overly aggressive senolytic therapy could theoretically impair these beneficial functions. This is a theoretical concern, not one documented in clinical trials, but it supports the intermittent dosing approach rather than continuous clearance.

Who Should Avoid Fisetin

• Pregnant or breastfeeding women (insufficient safety data)
• Patients on chemotherapy (potential interactions and unclear effects on treatment-induced senescence, which may serve anti-tumor functions)
• Patients with active infections (senescent cells play roles in immune defense)
• Individuals under 30 (senescent cell burden is typically low; the risk-benefit calculus changes)

Evidence Grading: Where Fisetin Stands

I grade every intervention I discuss, because patients deserve to know where on the evidence spectrum a therapy sits:

This is not a therapy with strong clinical evidence. It is a therapy with strong scientific rationale and emerging human data. The distinction matters.

What I Tell Patients Considering Fisetin

In my clinical practice, here is how I frame fisetin for patients:

1. The science is promising. The preclinical data is strong, the mechanism is well characterized, and the Mayo Clinic is taking it seriously enough to conduct multiple human trials. This is not fringe science.

2. The human evidence is early. We do not yet have definitive proof that fisetin clears senescent cells in humans at achievable oral doses. The AFFIRM-LITE results were modestly encouraging, not definitive.

3. Bioavailability is a real problem. Standard fisetin supplements may not achieve senolytic concentrations. Liposomal formulations and fat co-administration help, but we cannot guarantee adequate tissue levels.

4. If you choose to use it, use it correctly. Intermittent high-dose protocols, not daily low-dose. Two consecutive days per month or quarter. With fat. Stop in between cycles.

5. It is not a standalone longevity strategy. Fisetin, even if fully effective as a senolytic, addresses one hallmark of aging. A comprehensive approach includes exercise, sleep optimization, metabolic health, and other evidence-based interventions.

6. I will update this recommendation as the evidence evolves. The larger human trials will provide clarity. Until then, this is a reasonable but not proven intervention for individuals who understand the evidence limitations.

The Bottom Line

Fisetin is the most promising natural senolytic compound identified to date. The preclinical data is striking — selective senescent cell clearance, reduced inflammation, extended lifespan in aged mice. The mechanism is well characterized and the safety profile is favorable.

But the data is promising and preliminary. The human evidence is emerging, not established. The bioavailability challenge is real and unresolved. Anyone who tells you fisetin is a proven anti-aging therapy is ahead of the evidence.

What I tell my patients: fisetin is worth knowing about. For individuals who are serious about longevity optimization, understand the evidence limitations, and are willing to use it in a rational intermittent protocol — it is a reasonable addition to a comprehensive strategy. It is not a substitute for the fundamentals, and it is not a guaranteed senolytic in humans at currently available doses.

The nuance matters. That is what separates responsible clinical practice from supplement marketing.

References

1. Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. PMID: 30279143.
2. Luo H, et al. Fisetin inhibits the PI3K/AKT/mTOR signaling pathway in senescent cells. Aging. 2017;9(12):2554-2567.
3. Jia S, et al. Fisetin induces apoptosis via HIF-1alpha-dependent pathways in human cancer cells. International Journal of Oncology. 2014;44(1):67-75. PMID: 24173677.
4. Zhu Y, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging. 2017;9(3):955-963. PMID: 28273655.
5. Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. PMID: 30616998.
6. Mehta P, et al. Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling. 2020;32(1):41-47.
7. Khan N, et al. Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling. 2013;19(2):151-162. PMID: 23121441.
8. Touil YS, et al. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochemical Pharmacology. 2011;82(11):1731-1739. PMID: 21864507.